24 November 2017
News and Views
Links and Services
This week's issue of the Journal of the American Medical Association compares 1 with 3 years of adjuvant imatinib for operable gastrointestinal stromal tumor.
Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors